Abstract
Steroid-refractory immune-related pneumonitis is a clinical challenge with limited evidence-based treatment strategies. Current guidelines recommend the use of immunosuppressants; however, the optimal type and dosage of these agents remain unclear. Herein, we report a case of steroid-refractory immune-related pneumonitis that was successfully treated with mycophenolate mofetil (MMF). The patient did not respond to high-dose steroid therapy as initial treatment but showed significant improvement in both subjective symptoms and imaging findings after the additional administration of MMF. Subsequent tapering of the MMF dose led to worsening imaging findings, which improved upon re-escalation of the MMF dose. This case highlights the potential efficacy of MMF for the treatment of steroid-refractory immune-related pneumonitis and provides valuable insights into the administration of MMF and its potential role in managing similar cases.